Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers By Ogkologos - March 5, 2025 759 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a systematic review of published studies Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR Managing Cancer Pain: Are Better Approaches on the Horizon? January 23, 2019 Cancer Immunotherapies Don’t Work for Everyone: HLA Gene May Explain Why January 27, 2022 EMA Recommends Granting a Marketing Authorisation for Lenalidomide Mylan October 23, 2020 County Denies Immunocompromised Employee’s Request to Work from Home During COVID-19 March 17, 2020 Load more HOT NEWS Progress in Treating GI Cancers Through Molecular Testing: The 2021 Advance... New Drug Regimen Cures More Children with Aggressive B-Cell Lymphoma Withdrawal of Application for the EMA Marketing Authorisation of Infigratinib Analysis of the Gut Microbiome Provides Clues to Survival Following Nivolumab...
